These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16729726)

  • 21. The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.
    Stockley JH; O'Neill C
    Biochem Soc Trans; 2007 Jun; 35(Pt 3):574-6. PubMed ID: 17511655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered beta-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer's disease brain.
    Stockley JH; Ravid R; O'Neill C
    FEBS Lett; 2006 Dec; 580(28-29):6550-60. PubMed ID: 17113083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathophysiology of the blood-brain barrier: animal models and methods.
    Hawkins BT; Egleton RD
    Curr Top Dev Biol; 2008; 80():277-309. PubMed ID: 17950377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro characterization of a gamma-secretase radiotracer in mammalian brain.
    Patel S; O'Malley S; Connolly B; Liu W; Hargreaves R; Sur C; Gibson RE
    J Neurochem; 2006 Jan; 96(1):171-8. PubMed ID: 16300641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 1. Anti-infective drugs.
    Adenot M; Perriere N; Scherrmann JM; Lahana R
    Chemotherapy; 2007; 53(1):70-2. PubMed ID: 17202814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of proBACE1 by glycosaminoglycans.
    Small DH; Klaver DW; Beckman M
    Neurodegener Dis; 2008; 5(3-4):206-8. PubMed ID: 18322391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
    Kreft AF; Martone R; Porte A
    J Med Chem; 2009 Oct; 52(20):6169-88. PubMed ID: 19694467
    [No Abstract]   [Full Text] [Related]  

  • 28. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases.
    Gabathuler R
    Neurobiol Dis; 2010 Jan; 37(1):48-57. PubMed ID: 19664710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects.
    Wu G; Sankaranarayanan S; Tugusheva K; Kahana J; Seabrook G; Shi XP; King E; Devanarayan V; Cook JJ; Simon AJ
    Clin Biochem; 2008 Aug; 41(12):986-96. PubMed ID: 18489907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prediction model for blood-brain barrier permeation and analysis on its parameter biologically.
    Chen Y; Zhu QJ; Pan J; Yang Y; Wu XP
    Comput Methods Programs Biomed; 2009 Sep; 95(3):280-7. PubMed ID: 19473718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential receptor-mediated drug targeting to the diseased brain.
    Rip J; Schenk GJ; de Boer AG
    Expert Opin Drug Deliv; 2009 Mar; 6(3):227-37. PubMed ID: 19327042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease.
    Matsumoto Y; Yanase D; Noguchi-Shinohara M; Ono K; Yoshita M; Yamada M
    Dement Geriatr Cogn Disord; 2007; 23(4):241-5. PubMed ID: 17310121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel non-peptide beta-secretase inhibitors derived from structure-based virtual screening and bioassay.
    Xu W; Chen G; Liew OW; Zuo Z; Jiang H; Zhu W
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3188-92. PubMed ID: 19447035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In silico prediction of blood brain barrier permeability: an Artificial Neural Network model.
    Garg P; Verma J
    J Chem Inf Model; 2006; 46(1):289-97. PubMed ID: 16426064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
    Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
    J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tetrahydroquinoline sulfonamides as gamma-secretase inhibitors.
    Asberom T; Bara TA; Clader JW; Greenlee WJ; Guzik HS; Josien HB; Li W; Parker EM; Pissarnitski DA; Song L; Zhang L; Zhao Z
    Bioorg Med Chem Lett; 2007 Jan; 17(1):205-7. PubMed ID: 17046254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges for blood-brain barrier (BBB) screening.
    Jeffrey P; Summerfield SG
    Xenobiotica; 2007; 37(10-11):1135-51. PubMed ID: 17968740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
    Arce MP; Rodríguez-Franco MI; González-Muñoz GC; Pérez C; López B; Villarroya M; López MG; García AG; Conde S
    J Med Chem; 2009 Nov; 52(22):7249-57. PubMed ID: 19856923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenic mechanisms in Alzheimer's disease.
    Pastorino L; Lu KP
    Eur J Pharmacol; 2006 Sep; 545(1):29-38. PubMed ID: 16904664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular modeling of blood-brain barrier nutrient transporters: in silico basis for evaluation of potential drug delivery to the central nervous system.
    Allen DD; Geldenhuys WJ
    Life Sci; 2006 Feb; 78(10):1029-33. PubMed ID: 16126231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.